R
RxSight, Inc. (RXST)
NGM – Real Time Price. Currency in USD
5.52
-0.18 (-3.16%)
At close: May 12, 2026, 4:00 PM EDT
5.52
0.00 (0.00%)
Pre-market: May 13, 2026, 5:40 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
5.52
-0.18 (-3.16%)
At close: May 12, 2026, 4:00 PM EDT
5.52
0.00 (0.00%)
Pre-market: May 13, 2026, 5:40 AM EDT
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
| Name | Position |
|---|---|
| Dr. Ilya Goldshleger Ph.D. | Chief Operating Officer |
| Dr. Ronald M. Kurtz M.D. | President, CEO & Director |
| Mr. Adam Dashe | Executive Vice President of International |
| Mr. Eric J. Weinberg | Chief Business Development Officer |
| Mr. Jim Schindler | Executive VP & General Counsel |
| Mr. Mark Wilterding | Chief Financial Officer |
| Mr. Oliver Moravcevic | Vice President of Investor Relations |
| Mr. Patrick Cullen | Executive VP of Quality & Infrastructure Operations |
| Mr. Scott Gaines | Chief Customer Officer |
| Ms. Maureen O'Connell | Executive VP of Clinical & Regulatory Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 10-Q | rxst-20260331.htm |
| 2026-04-28 | DEFA14A | 2026_defa14a_12312025_ad.htm |
| 2026-04-28 | DEF 14A | rxst-20260427.htm |
| 2026-03-19 | 8-K/A | d115727d8ka.htm |
| 2026-02-25 | S-8 | rxst-20260225.htm |
| 2026-02-25 | POS AM | d33924dposam.htm |
| 2026-02-13 | POSASR | d109582dposasr.htm |
| 2026-01-12 | 8-K | rxst-20260111.htm |
| 2025-12-23 | 8-K | rxst-20251223.htm |
| 2025-12-22 | 8-K | d19913d8k.htm |